Arthur Kuan - Chief Executive Officer
Arthur currently serves as Chief Executive Officer and Director on the Board at Cold Genesys, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.
Paola Grandi, Ph.D. - Chief Scientific Officer
Paola is widely regarded as a scientific leader in the field of immuno-oncology and is responsible for directing the clinical and translational research program at Cold Genesys. Paola earned a Ph.D. in Biochemistry from the University of Ferrara (Italy) in 2001 before moving to the U.S. to pursue her interests in oncolytic Herpes Simplex Virus-based vectors for the treatment of recurrent malignant glioblastoma. After four years of post-doctoral research at the Massachusetts General Hospital in Boston, Paola joined the Departments of Neurological Surgery and Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine where she developed the next-generation Oncolytic HSV-based vectors armed with novel payload combinations that altered the tumor microenvironment (TME) to promote the development of anti-tumor immunity. As an NIH funded principal investigator, she carried out pioneering work to combine the use of retargeted HSV vectors with cellular microRNA regulation of viral genes in non-tumor tissue to limit vector oncolytic activity to brain tumors. Her academic research produced several key patents that provided the core technologies to establish a start-up oncolytic vector company, Oncorus, Inc. in Cambridge, MA as company co-founder, scientific advisory board member and early stage director of company research.
Bing Kung - Vice President, Business Development
Bing has over thirteen years of life science industry experience as a business development executive, investment banker and scientist. He has been involved in over 75 partnership, M&A and financing transactions in the life science sector, including those for immuno-oncology and platform technology companies. Most recently, Bing managed business development activities at Ascendancy Healthcare, which provided Western-based companies partnership solutions enabling entry and commercialization of their biopharmaceutical products into China and other high-growth Asian markets. Previously, he served as Vice President at Torreya Partners, a boutique life science investment bank, and also worked at MTS Health Partners and Aquilo Partners. Bing began his career as a research scientist in the Divisions of Oncology and Neurology at The Children's Hospital of Philadelphia, where he authored a number of peer-reviewed publications on the molecular basis of the pediatric solid tumor neuroblastoma. He received his Master's in Biotechnology and his Bachelor’s in Biology from the University of Pennsylvania.
Amy Steele - Vice President, Controller
Amy joined Cold Genesys as Vice President, Controller in July 2016 and is responsible for Gold Genesys’ global finance and accounting activities. Prior to joining Cold Genesys, she served as the Associate Director, Finance & Business Operations at TWi Pharmaceuticals USA, Inc. and Genovi Pharmaceuticals, Inc. and was responsible for setting up of multiple corporate entities in the US, UK and Taiwan, implementing global ERP system, obtaining state wholesale and virtual manufacturing licenses for generic products as well as transfer pricing analysis. Amy brings many years of experience in financing, accounting and internal audit and received her BA degree in Business Economics / Accounting from University of California Los Angeles.
Bradley Grimm - Director, Manufacturing
Brad has worked in the life sciences industry for over 25 years, with a specific focus on viral-based therapeutics and vaccines. Brad began his career in this field at Chiron Therapeutics’ gene therapy division in San Diego, performing all aspects of their retroviral production process, from initial cell culture through final product lyophilization. In addition to over a decade of work in the Process Development and cGMP Manufacturing departments at Chiron, Brad also worked at GenStar Therapeutics, performing process optimization and cGMP tech transfer for their adenovirus-based therapies, as well as Telos Pharmaceuticals, where he focused on development of cell culture systems for activated T-cell lines. Most recently prior to joining the Somatek consulting group, Brad spent twelve years as a Process Development scientist at MilliporeSigma’s viral vaccine and gene therapy Contract Manufacturing facility. In this capacity, he helped develop and optimize production processes for multiple clients and oversaw their transfer for successful cGMP Manufacturing production.